US official questions clinical researcher reimbursement practice
This article was originally published in Clinica
Executive Summary
A key federal health official has signalled his intent to scrutinise the common practice of paying researchers involved in clinical trials with a share of the equity in medical device, biologic or pharmaceutical companies that own the products that are the subject of the trials.